Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer

Alan P. Lombard, Liangren Liu, Vito Cucchiara, Chengfei Liu, Cameron M. Armstrong, Ruining Zhao, Joy C. Yang, Wei Lou, Christopher P Evans, Allen C Gao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Current treatments for castration resistant prostate cancer (CRPC) largely fall into two classes: androgen receptor (AR)targeted therapies such as the next-generation antiandrogen therapies (NGAT), enzalutamide and abiraterone, and taxanes such as docetaxel and cabazitaxel. Despite improvements in outcomes, patients still succumb to the disease due to the development of resistance. Further complicating the situation is lack of a well-defined treatment sequence and potential for cross-resistance between therapies. We have developed several models representing CRPC with acquired therapeutic resistance. Here, we utilized these models to assess putative cross-resistance between treatments. We find that resistance to enzalutamide induces resistance to abiraterone and vice versa, but resistance to neither alters sensitivity to taxanes. Acquired resistance to docetaxel induces cross-resistance to cabazitaxel but not to enzalutamide or abiraterone. Correlating responses with known mechanisms of resistance indicates that AR variants are associated with resistance to NGATs, whereas the membrane efflux protein ABCB1 is associated with taxane resistance. Mechanistic studies show that AR variant-7 (AR-v7) is involved in NGAT resistance but not resistance to taxanes. Our findings suggest the existence of intra cross-resistance within a drug class (i.e., within NGATs or within taxanes), whereas inter cross-resistance between drug classes does not develop. Furthermore, our data suggest that resistance mechanisms differ between drug classes. These results may have clinical implications by showing that treatments of one class can be sequenced with those of another, but caution should be taken when sequencing similar classed drugs. In addition, the development and use of biomarkers indicating resistance will improve patient stratification for treatment.

Original languageEnglish (US)
Pages (from-to)2197-2205
Number of pages9
JournalMolecular Cancer Therapeutics
Volume17
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Taxoids
docetaxel
Therapeutics
Androgen Antagonists
Castration
taxane
Pharmaceutical Preparations
Drug Resistance
Membrane Proteins
Biomarkers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. / Lombard, Alan P.; Liu, Liangren; Cucchiara, Vito; Liu, Chengfei; Armstrong, Cameron M.; Zhao, Ruining; Yang, Joy C.; Lou, Wei; Evans, Christopher P; Gao, Allen C.

In: Molecular Cancer Therapeutics, Vol. 17, No. 10, 01.10.2018, p. 2197-2205.

Research output: Contribution to journalArticle

Lombard, Alan P. ; Liu, Liangren ; Cucchiara, Vito ; Liu, Chengfei ; Armstrong, Cameron M. ; Zhao, Ruining ; Yang, Joy C. ; Lou, Wei ; Evans, Christopher P ; Gao, Allen C. / Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. In: Molecular Cancer Therapeutics. 2018 ; Vol. 17, No. 10. pp. 2197-2205.
@article{5124122c734d46f79834a8467cdf99bf,
title = "Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer",
abstract = "Current treatments for castration resistant prostate cancer (CRPC) largely fall into two classes: androgen receptor (AR)targeted therapies such as the next-generation antiandrogen therapies (NGAT), enzalutamide and abiraterone, and taxanes such as docetaxel and cabazitaxel. Despite improvements in outcomes, patients still succumb to the disease due to the development of resistance. Further complicating the situation is lack of a well-defined treatment sequence and potential for cross-resistance between therapies. We have developed several models representing CRPC with acquired therapeutic resistance. Here, we utilized these models to assess putative cross-resistance between treatments. We find that resistance to enzalutamide induces resistance to abiraterone and vice versa, but resistance to neither alters sensitivity to taxanes. Acquired resistance to docetaxel induces cross-resistance to cabazitaxel but not to enzalutamide or abiraterone. Correlating responses with known mechanisms of resistance indicates that AR variants are associated with resistance to NGATs, whereas the membrane efflux protein ABCB1 is associated with taxane resistance. Mechanistic studies show that AR variant-7 (AR-v7) is involved in NGAT resistance but not resistance to taxanes. Our findings suggest the existence of intra cross-resistance within a drug class (i.e., within NGATs or within taxanes), whereas inter cross-resistance between drug classes does not develop. Furthermore, our data suggest that resistance mechanisms differ between drug classes. These results may have clinical implications by showing that treatments of one class can be sequenced with those of another, but caution should be taken when sequencing similar classed drugs. In addition, the development and use of biomarkers indicating resistance will improve patient stratification for treatment.",
author = "Lombard, {Alan P.} and Liangren Liu and Vito Cucchiara and Chengfei Liu and Armstrong, {Cameron M.} and Ruining Zhao and Yang, {Joy C.} and Wei Lou and Evans, {Christopher P} and Gao, {Allen C}",
year = "2018",
month = "10",
day = "1",
doi = "10.1158/1535-7163.MCT-17-1269",
language = "English (US)",
volume = "17",
pages = "2197--2205",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer

AU - Lombard, Alan P.

AU - Liu, Liangren

AU - Cucchiara, Vito

AU - Liu, Chengfei

AU - Armstrong, Cameron M.

AU - Zhao, Ruining

AU - Yang, Joy C.

AU - Lou, Wei

AU - Evans, Christopher P

AU - Gao, Allen C

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Current treatments for castration resistant prostate cancer (CRPC) largely fall into two classes: androgen receptor (AR)targeted therapies such as the next-generation antiandrogen therapies (NGAT), enzalutamide and abiraterone, and taxanes such as docetaxel and cabazitaxel. Despite improvements in outcomes, patients still succumb to the disease due to the development of resistance. Further complicating the situation is lack of a well-defined treatment sequence and potential for cross-resistance between therapies. We have developed several models representing CRPC with acquired therapeutic resistance. Here, we utilized these models to assess putative cross-resistance between treatments. We find that resistance to enzalutamide induces resistance to abiraterone and vice versa, but resistance to neither alters sensitivity to taxanes. Acquired resistance to docetaxel induces cross-resistance to cabazitaxel but not to enzalutamide or abiraterone. Correlating responses with known mechanisms of resistance indicates that AR variants are associated with resistance to NGATs, whereas the membrane efflux protein ABCB1 is associated with taxane resistance. Mechanistic studies show that AR variant-7 (AR-v7) is involved in NGAT resistance but not resistance to taxanes. Our findings suggest the existence of intra cross-resistance within a drug class (i.e., within NGATs or within taxanes), whereas inter cross-resistance between drug classes does not develop. Furthermore, our data suggest that resistance mechanisms differ between drug classes. These results may have clinical implications by showing that treatments of one class can be sequenced with those of another, but caution should be taken when sequencing similar classed drugs. In addition, the development and use of biomarkers indicating resistance will improve patient stratification for treatment.

AB - Current treatments for castration resistant prostate cancer (CRPC) largely fall into two classes: androgen receptor (AR)targeted therapies such as the next-generation antiandrogen therapies (NGAT), enzalutamide and abiraterone, and taxanes such as docetaxel and cabazitaxel. Despite improvements in outcomes, patients still succumb to the disease due to the development of resistance. Further complicating the situation is lack of a well-defined treatment sequence and potential for cross-resistance between therapies. We have developed several models representing CRPC with acquired therapeutic resistance. Here, we utilized these models to assess putative cross-resistance between treatments. We find that resistance to enzalutamide induces resistance to abiraterone and vice versa, but resistance to neither alters sensitivity to taxanes. Acquired resistance to docetaxel induces cross-resistance to cabazitaxel but not to enzalutamide or abiraterone. Correlating responses with known mechanisms of resistance indicates that AR variants are associated with resistance to NGATs, whereas the membrane efflux protein ABCB1 is associated with taxane resistance. Mechanistic studies show that AR variant-7 (AR-v7) is involved in NGAT resistance but not resistance to taxanes. Our findings suggest the existence of intra cross-resistance within a drug class (i.e., within NGATs or within taxanes), whereas inter cross-resistance between drug classes does not develop. Furthermore, our data suggest that resistance mechanisms differ between drug classes. These results may have clinical implications by showing that treatments of one class can be sequenced with those of another, but caution should be taken when sequencing similar classed drugs. In addition, the development and use of biomarkers indicating resistance will improve patient stratification for treatment.

UR - http://www.scopus.com/inward/record.url?scp=85054079718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054079718&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-1269

DO - 10.1158/1535-7163.MCT-17-1269

M3 - Article

VL - 17

SP - 2197

EP - 2205

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -